Clinical trials: Appetite Suppression
Severe to Morbid Obesity and Type 2 Diabetes
Study of Weight Loss Using Gastric Stimulation in Obese Patients With Type 2 Diabetes
The purpose of this study is to test the effect of an implanted device that stimulates the stomach on weight loss in patients suffering from obesity and type 2 diabetes.
- Trial name
- ASSIST (NCT00200018)
- Testing
- Enterra Therapy System (H9900014)
- Where
- 2 sites in United States
- Volunteers
- 46 people
- Sponsor
- MedtronicNeuro
Metabolic Syndrome
The BANGALORE Study; Combination of Berberine, Lipoic Acid, and Picrorhiza
Though medical treatment has been effective in the treatment of cardiometabolic diseases (including coronary atherosclerosis and diabetes mellitus), the incidence of these disorders continues to be high.
- Trial name
- CAR-191 (NCT01696448)
- Testing
- CAR-191
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Carmel Biosciences
Appetite Regulation, Appetite Suppression
Efficacy and Safety of IQP-AK-102 in Reducing Appetite
The primary cause of being overweight is an imbalance in calories consumed and energy expenditure. A surplus in energy intake might result in body fat deposition and thereby body weight gain.
- Conditions
- Appetite Regulation, Appetite Suppression, Energy Intake
- Trial name
- NCT02774486
- Testing
- IQP-AK-102
- Where
- Germany
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- InQpharm Group
Weight Loss
ELIRA 2: Safety and Effectiveness of TENS Assisted Weight Loss and Appetite Suppression
The objectives of this study are to demonstrate safety and effectiveness of a wearable patch TENS system (Appendix 2) in driving weight loss and appetite suppression when coupled with an integrated weight loss reduction strategy.
- Trial name
- ELIRA_2 (NCT03936699)
- Testing
- Transcutaneous Nerve Stimulator (TENS), Diet & Exercise
- Where
- United States
- Volunteers
- 161 people
- Sponsor
- Elira Therapeutics, Inc.
Overweight, Obesity
A Controlled Study to Evaluate the Effects of a Supplement on Weight Loss, Blood Sugar, and Appetite Suppression
This is a randomized, controlled, hybrid clinical trial evaluating the effects of the Evolv GLP-1 supplement on weight loss, blood sugar regulation, and appetite suppression over 12 weeks.
- Conditions
- Overweight, Obesity, Blood Sugar Regulation, Appetite Suppression
- Trial name
- NCT07889570
- Testing
- Evolv GLP-1 Group, Control Group
- Where
- United States
- Volunteers
- 98 people, healthy volunteers welcome
- Sponsor
- Evolv